Literature DB >> 17650826

Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria.

Mine Ozkan1, Serap Batmaz Oflaz, Nazmiye Kocaman, Ferhan Ozseker, Ash Gelincik, Suna Büyüköztürk, Sedat Ozkan, Bahattin Colakoğlu.   

Abstract

BACKGROUND: Chronic idiopathic urticaria (CIU) is a frequently occurring disease that has a great impact on the health-related quality of life (HRQL) of patients and seems to be associated with a number of psychological factors.
OBJECTIVES: To determine the prevalence of psychiatric morbidity in patients with CIU and to determine HRQL of CIU patients compared with controls.
METHODS: A semistructured interview form, a generic form of the HRQL questionnaire (Medical Outcomes Study 36-Item Short-Form Health Survey [SF-36]), and the Structured Clinical Interview for DSM-IV Axis Disorders (SCID-I) were administered to CIU patients who presented to the Allergy Department of the University of Istanbul (from January 1 to April 30, 2005). Healthy subjects matched sociodemographically with the study group were used as the control group.
RESULTS: Eighty-four CIU patients and 75 controls were included in the study. The mean +/- SD age of the study participants was 36.83 +/- 10.26 years, and 84% were women. The mean +/- SD duration of the disease was 6.34 +/- 7.2 years, and symptoms were intermittent in 51%. The SCID-I revealed a psychiatric diagnosis in 60% of the patients. In terms of the distribution of psychiatric diagnoses, the most frequently occurring diagnosis was depressive disorders (40%). Most patients (81%) believed that their illnesses were due to stress. The subdomains on the SF-36 measurements were significantly lower than those of the control subjects (P < or = .005). The physical function, vitality, and mental health subdomains of the SF-36 in the patients with a psychiatric diagnosis were significantly lower (P < .05).
CONCLUSION: These findings suggested that psychiatric morbidity is high among ICU patients and is detrimental to their quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 17650826     DOI: 10.1016/S1081-1206(10)60617-5

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  17 in total

1.  [Chronic urticaria. Prevalence, course, prognostic factors and impact].

Authors:  K Weller; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 2.  Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Authors:  Claus Bachert; Marcus Maurer
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care.

Authors:  Sinisa Savic; Alexander Marsland; David McKay; Michael R Ardern-Jones; Tabi Leslie; Olivier Somenzi; Laura Baldock; Clive Grattan
Journal:  Allergy Asthma Clin Immunol       Date:  2015-07-21       Impact factor: 3.406

4.  A rapid method of detecting autoantibody against FcεRIα for chronic spontaneous urticaria.

Authors:  Mey-Fann Lee; Tzu-Mei Lin; Szu-Wei Liu; Yi-Hsing Chen
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

5.  Autologous serum and plasma skin test to predict 2-year outcome in chronic spontaneous urticaria.

Authors:  Tadech Boonpiyathad; Atik Sangasapaviliya
Journal:  Asia Pac Allergy       Date:  2016-10-31

6.  Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria.

Authors:  Won-Sun Choi; Eun-Soo Lim; Ga-Young Ban; Ji-Hye Kim; Yoo-Seob Shin; Hae-Sim Park; Young-Min Ye
Journal:  Korean J Intern Med       Date:  2016-06-01       Impact factor: 2.884

7.  Sense of coherence as a protective factor in chronic urticaria.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Pietrzak; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

Review 8.  Psychoneuroimmunoendocrinology: clinical implications.

Authors:  Sandra Nora González-Díaz; Alfredo Arias-Cruz; Bárbara Elizondo-Villarreal; Olga Patricia Monge-Ortega
Journal:  World Allergy Organ J       Date:  2017-06-06       Impact factor: 4.084

9.  Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.

Authors:  Werner Aberer
Journal:  Arch Drug Inf       Date:  2009-06

10.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.